Carlo Remotti

This recital by Jean-Francois Borras honours the fascinating history of the Opera de Monte-Carlo, the house that has performed more French repertoire than any other. Jean-Francois Borras, who received his initial training in the choir of the Monte-Carlo Cathedral and is an internationally-renowned ambassador of French vocal style, presents excerpts from works by Mascagni, Gunsbourg and Massenet that were composed for the Opera there. Raoul Gunsbourg was the director of the Opera de Monte Carlo (architect Charles Garnier) from 1893-1951 and the variety of his programming created the institution's exceptional renown. Borras sings arias from operas that he has performed on the stage of the Opera de Monte-Carlo, including Romeo et Juliette (Gounod), Manon, Herodiade, Werther (Massenet), Carmen (Bizet) and Les Contes d'Hoffmann (Offenbach), accompanied by the Orchestre Philharmonique de Monte Carlo under Pierre Dumoussaud, a young French conductor and specialist in operatic repertoire who is rapidly building an international career.

This absorbing project finds Australian composer Brett Dean and Estonian composer Erkki-Sven Tüür drawing inspiration in very different ways from the music, life and times of Carlo Gesualdo and juxtaposes these reflections with Gesualdo’s own music. The music of Carlo Gesualdo, Prince of Venosa (1566-1613) has exerted a powerful influence on composers down the ages. His highly-charged, mannerist, idiosyncratic vocal music constitutes “a gallery of dramatically-lit portraits of human emotions with a heavy emphasis on the extremes of joy and despair” (to quote former Hilliard Ensemble singer Gordon Jones).

Modern cancer treatment relies on Monte Carlo simulations to help radiotherapists and clinical physicists better understand and compute radiation dose from imaging devices as well as exploit four-dimensional imaging data. With Monte Carlo-based treatment planning tools now available from commercial vendors, a complete transition to Monte Carlo-based dose calculation methods in radiotherapy could likely take place in the next decade.